Chemotherapy for hepatitis B: New treatment options necessitate reappraisal of traditional endpoints
- 1 December 2002
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 123 (6) , 2135-2140
- https://doi.org/10.1053/gast.2002.37288
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In VitroAntimicrobial Agents and Chemotherapy, 2002
- Viral dynamics during and after entecavir therapy in patients with chronic hepatitis BJournal of Hepatology, 2002
- Viral dynamics in chronic hepatitis B patients during lamivudine therapyLiver International, 2002
- Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology, 2001
- Occult Hepatitis B Virus Infection: A Hidden Menace?Hepatology, 2001
- Combination Chemotherapy for Hepatitis B VirusDrugs, 2000
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999
- Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitisLiver International, 1995